Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s56, 2021. DOI: 10.25251/skin.5.supp.56. Disponível em: https://skin.dermsquared.com/skin/article/view/1407. Acesso em: 18 apr. 2025.